From one to many: Hypertonia in schizophrenia spectrum psychosis an integrative review and adversarial collaboration report.

Adversarial collaboration Catatonia Drug-induced parkinsonism Gegenhalten Hypertonia Paratonia Reticular formation Rigidity Schizophrenia Supplementary motor area

Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
12 Apr 2023
Historique:
received: 29 09 2022
revised: 14 03 2023
accepted: 15 03 2023
entrez: 14 4 2023
pubmed: 15 4 2023
medline: 15 4 2023
Statut: aheadofprint

Résumé

Different types of resistance to passive movement, i.e. hypertonia, were described in schizophrenia spectrum disorders (SSD) long before the introduction of antipsychotics. While these have been rediscovered in antipsychotic-naïve patients and their non-affected relatives, the existence of intrinsic hypertonia vs drug-induced parkinsonism (DIP) in treated SSD remains controversial. This integrative review seeks to develop a commonly accepted framework to specify the putative clinical phenomena, highlight conflicting issues and discuss ways to challenge each hypothesis and model through adversarial collaboration. The authors agreed on a common framework inspired from systems neuroscience. Specification of DIP, locomotor paratonia (LMP) and psychomotor paratonia (PMP) identified points of disagreement. Some viewed parkinsonian rigidity to be sufficient for diagnosing DIP, while others viewed DIP as a syndrome that should include bradykinesia. Sensitivity of DIP to anticholinergic drugs and the nature of LPM and PMP were the most debated issues. It was agreed that treated SSD should be investigated first. Clinical features of the phenomena at issue could be confirmed by torque, EMG and joint angle measures that could help in challenging the selectivity of DIP to anticholinergics. LMP was modeled as the release of the reticular formation from the control of the supplementary motor area (SMA), which could be challenged by the tonic vibration reflex or acoustic startle. PMP was modeled as the release of primary motor cortex from the control of the SMA and may be informed by subclinical echopraxia. If these challenges are not met, this would put new constraints on the models and have clinical and therapeutic implications.

Identifiants

pubmed: 37059654
pii: S0920-9964(23)00125-1
doi: 10.1016/j.schres.2023.03.031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Authors have no conflict of interest to declare related to the current manuscript.

Auteurs

Jack R Foucher (JR)

ICube - CNRS UMR 7357, Neurophysiology, FMTS, University of Strasbourg, France, EU; CEMNIS - Noninvasive Neuromodulation Center, University Hospital Strasbourg, France, EU. Electronic address: jack.foucher@unistra.fr.

Dusan Hirjak (D)

Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, EU.

Sebastian Walther (S)

Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland.

Ludovic C Dormegny-Jeanjean (LC)

ICube - CNRS UMR 7357, Neurophysiology, FMTS, University of Strasbourg, France, EU; CEMNIS - Noninvasive Neuromodulation Center, University Hospital Strasbourg, France, EU.

Ilia Humbert (I)

CEMNIS - Noninvasive Neuromodulation Center, University Hospital Strasbourg, France, EU.

Olivier Mainberger (O)

ICube - CNRS UMR 7357, Neurophysiology, FMTS, University of Strasbourg, France, EU; CEMNIS - Noninvasive Neuromodulation Center, University Hospital Strasbourg, France, EU.

Clément C de Billy (CC)

ICube - CNRS UMR 7357, Neurophysiology, FMTS, University of Strasbourg, France, EU; CEMNIS - Noninvasive Neuromodulation Center, University Hospital Strasbourg, France, EU.

Benoit Schorr (B)

Pôle de Psychiatrie, Santé Mentale et Addictologie, University Hospital Strasbourg, France, EU; Physiopathologie et Psychopathologie Cognitive de la Schizophrénie - INSERM 1114, FMTS, University of Strasbourg, France, EU.

Laurent Vercueil (L)

Unité de neurophysiologie clinique, CHU Grenoble Alpes, Université Grenoble Alpes, France, EU; INSERM U1216, Institut de neurosciences, Grenoble, France, EU.

Jonathan Rogers (J)

Division of Psychiatry, University College London, London, UK; South London and Maudsley NHS Foundation Trust, London, UK.

Gabor Ungvari (G)

Section of Psychiatry, School of Medicine, University Notre Dame Australia, Fremantle, Australia.

John Waddington (J)

School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland, EU.

Fabrice Berna (F)

Pôle de Psychiatrie, Santé Mentale et Addictologie, University Hospital Strasbourg, France, EU; Physiopathologie et Psychopathologie Cognitive de la Schizophrénie - INSERM 1114, FMTS, University of Strasbourg, France, EU.

Classifications MeSH